Trials / Completed
CompletedNCT03161288
A Study of KY1005 in Healthy Volunteers
A Single and Multiple Ascending Dose, Placebo-Controlled, Double-Blind, Phase 1 Study of KY1005 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Kymab Limited · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a single and multiple ascending dose, placebo-controlled, double-blind, Phase 1 study to evaluate the safety and tolerability of KY1005 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KY1005 | A human anti-OX40 ligand monoclonal antibody |
| DRUG | Placebo | Matched placebo |
Timeline
- Start date
- 2017-05-29
- Primary completion
- 2018-03-30
- Completion
- 2018-03-30
- First posted
- 2017-05-19
- Last updated
- 2019-08-29
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03161288. Inclusion in this directory is not an endorsement.